KR20110125256A - 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 - Google Patents

티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 Download PDF

Info

Publication number
KR20110125256A
KR20110125256A KR1020117022785A KR20117022785A KR20110125256A KR 20110125256 A KR20110125256 A KR 20110125256A KR 1020117022785 A KR1020117022785 A KR 1020117022785A KR 20117022785 A KR20117022785 A KR 20117022785A KR 20110125256 A KR20110125256 A KR 20110125256A
Authority
KR
South Korea
Prior art keywords
methyl
thieno
pyrimidine
methylethyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117022785A
Other languages
English (en)
Korean (ko)
Inventor
사이먼 데이비드 가일
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20110125256A publication Critical patent/KR20110125256A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020117022785A 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 Withdrawn KR20110125256A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
SE0300119-5 2003-01-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057013126A Division KR101107486B1 (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Publications (1)

Publication Number Publication Date
KR20110125256A true KR20110125256A (ko) 2011-11-18

Family

ID=20290154

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117022785A Withdrawn KR20110125256A (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도
KR1020057013126A Expired - Fee Related KR101107486B1 (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057013126A Expired - Fee Related KR101107486B1 (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Country Status (23)

Country Link
US (2) US7384951B2 (https=)
EP (1) EP1587812B1 (https=)
JP (1) JP4519121B2 (https=)
KR (2) KR20110125256A (https=)
CN (1) CN100334093C (https=)
AT (1) ATE335748T1 (https=)
AU (1) AU2004206012B2 (https=)
BR (1) BRPI0406801B8 (https=)
CA (1) CA2512441C (https=)
DE (1) DE602004001857T2 (https=)
EG (1) EG25613A (https=)
ES (1) ES2270337T3 (https=)
IL (1) IL169370A (https=)
IS (1) IS2376B (https=)
MX (1) MXPA05007496A (https=)
NO (1) NO333702B1 (https=)
NZ (1) NZ541217A (https=)
PL (1) PL214682B1 (https=)
RU (1) RU2331647C2 (https=)
SE (1) SE0300119D0 (https=)
UA (1) UA81788C2 (https=)
WO (1) WO2004065394A1 (https=)
ZA (1) ZA200505364B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI624290B (zh) * 2016-03-17 2018-05-21 高爾縱股份有限公司 實現於螢幕高爾夫系統的內容傳輸服務方法、用於內容傳輸服務的移動終端的控制方法及存儲其的電腦可讀存儲介質
TWI624292B (zh) * 2016-03-17 2018-05-21 高爾縱股份有限公司 虛擬高爾夫類比裝置、用於虛擬高爾夫的影像實現方法及存儲其的電腦可讀存儲介質
TWI626975B (zh) * 2016-03-17 2018-06-21 高爾縱股份有限公司 虛擬高爾夫類比裝置、用於虛擬高爾夫的影像實現方法及存儲其的電腦可讀存儲介質

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) * 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
PT2411395E (pt) * 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
DK2411397T3 (da) * 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2804852A2 (en) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutic compounds
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
MY184561A (en) * 2013-10-21 2021-04-03 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
CA2974697A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CN119080799B (zh) * 2024-09-27 2025-12-05 山东大学 一种n-羟基噻吩并嘧啶二酮类衍生物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
IL136499A0 (en) 1997-12-05 2001-06-14 Astrazeneca Uk Ltd Astrazeneca Pyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pypyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pyridazinone compounds, process for their preparatioridaziones compounds, process for their preparation, pharmaceutical compositions containing them, a n, pharmaceutical compositions containing them, a process for prepating the pharmaceutical compositiprocess for preparing the pharmaceutical compositions, and use thereof ons, and use thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ATE253580T1 (de) * 1998-08-28 2003-11-15 Astrazeneca Ab Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie
ATE272642T1 (de) * 2000-05-04 2004-08-15 Astrazeneca Ab Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI624290B (zh) * 2016-03-17 2018-05-21 高爾縱股份有限公司 實現於螢幕高爾夫系統的內容傳輸服務方法、用於內容傳輸服務的移動終端的控制方法及存儲其的電腦可讀存儲介質
TWI624292B (zh) * 2016-03-17 2018-05-21 高爾縱股份有限公司 虛擬高爾夫類比裝置、用於虛擬高爾夫的影像實現方法及存儲其的電腦可讀存儲介質
TWI626975B (zh) * 2016-03-17 2018-06-21 高爾縱股份有限公司 虛擬高爾夫類比裝置、用於虛擬高爾夫的影像實現方法及存儲其的電腦可讀存儲介質

Also Published As

Publication number Publication date
CN1761672A (zh) 2006-04-19
IL169370A (en) 2011-05-31
ES2270337T3 (es) 2007-04-01
NZ541217A (en) 2008-05-30
JP4519121B2 (ja) 2010-08-04
IS7965A (is) 2005-07-29
AU2004206012A1 (en) 2004-08-05
IL169370A0 (en) 2007-07-04
CA2512441C (en) 2012-01-03
RU2331647C2 (ru) 2008-08-20
IS2376B (is) 2008-07-15
PL214682B1 (pl) 2013-09-30
EP1587812A1 (en) 2005-10-26
DE602004001857T2 (de) 2007-05-24
ZA200505364B (en) 2006-09-27
MXPA05007496A (es) 2005-09-21
ATE335748T1 (de) 2006-09-15
DE602004001857D1 (de) 2006-09-21
WO2004065394A1 (en) 2004-08-05
US20060052400A1 (en) 2006-03-09
KR20050092760A (ko) 2005-09-22
RU2005121494A (ru) 2006-02-10
KR101107486B1 (ko) 2012-01-19
HK1081959A1 (en) 2006-05-26
UA81788C2 (uk) 2008-02-11
JP2006516974A (ja) 2006-07-13
NO20053826L (no) 2005-10-17
CA2512441A1 (en) 2004-08-05
BRPI0406801B8 (pt) 2021-05-25
SE0300119D0 (sv) 2003-01-17
CN100334093C (zh) 2007-08-29
EG25613A (en) 2012-03-22
NO333702B1 (no) 2013-08-26
EP1587812B1 (en) 2006-08-09
BRPI0406801A (pt) 2006-01-17
NO20053826D0 (no) 2005-08-15
AU2004206012B2 (en) 2007-06-14
BRPI0406801B1 (pt) 2018-04-03
US20080214579A1 (en) 2008-09-04
PL378222A1 (pl) 2006-03-20
US7384951B2 (en) 2008-06-10

Similar Documents

Publication Publication Date Title
KR101107486B1 (ko) 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도
AU2005214379B2 (en) Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
US6300334B1 (en) Thieno[2,3-d]pyrimidine-2,4-diones
US7361660B2 (en) Chemical compounds
KR100897469B1 (ko) 티에노피리미딘디온 및 그의 자가면역 질환의 조절에있어서의 용도
KR20050092759A (ko) 신규 화합물
US20080221131A1 (en) Thienopyrimidinediones and their use in modulation of autoimmune disease
US6890923B2 (en) Compounds
HK1081959B (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
CN100354282C (zh) 噻吩并哒嗪酮及其在调节自身免疫疾病中的用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110928

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid